Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions

Neurogenic Bladder Disorder Clinical Trial

Official title: A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy

Status Terminated

Clinical Trial Summary

This study will assess the safety, tolerability and efficacy of SAF312 in patients with overactive bladder disease due to spinal cord lesions. The overactive bladder of patients who qualify for this study is insufficiently managed by antimuscarinic therapy, or patients poorly tolerate the treatment with antimuscarinic drugs. The efficacy of SAF312 will be primarily determined via urodynamic measurements.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Neurogenic Bladder Disorder
• Neurogenic Bladder, Spastic
• Neurogenic Bladder, Uninhibited
• Neurogenic Dysfunction of the Urinary Bladder
• Neurogenic Urinary Bladder
• Urinary Bladder Diseases
• Urinary Bladder, Neurogenic
• Urinary Bladder, Overactive

• NCT number: NCT01598103
• Study type: Interventional
• Source: Novartis
• Status: Terminated
• Phase: Phase 2
• Start date: January 2012
• Completion date: September 2012